Total Payments
$381,757
2024 Payments
$41,748
Companies
66
Transactions
1,643
Medicare Patients
1,663
Medicare Billing
$1.3M
Payment Breakdown by Category
Consulting$169,805 (44.5%)
Other$146,727 (38.4%)
Travel$36,263 (9.5%)
Food & Beverage$28,367 (7.4%)
Education$596.17 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $169,805 | 42 | 44.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $146,727 | 61 | 38.4% |
| Travel and Lodging | $36,263 | 112 | 9.5% |
| Food and Beverage | $28,367 | 1,417 | 7.4% |
| Education | $596.17 | 11 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73,844 | 250 | $0 (2024) |
| Genentech USA, Inc. | $65,424 | 65 | $0 (2024) |
| Biogen, Inc. | $64,792 | 169 | $0 (2024) |
| GENZYME CORPORATION | $59,353 | 93 | $0 (2024) |
| Celgene Corporation | $47,864 | 116 | $0 (2024) |
| EMD Serono, Inc. | $39,670 | 116 | $0 (2024) |
| TG Therapeutics, Inc. | $18,368 | 56 | $0 (2024) |
| ABBVIE INC. | $1,860 | 143 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $964.81 | 84 | $0 (2022) |
| Allergan, Inc. | $789.31 | 62 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,748 | 268 | EMD Serono, Inc. ($18,947) |
| 2023 | $49,898 | 221 | GENZYME CORPORATION ($15,278) |
| 2022 | $10,463 | 289 | GENZYME CORPORATION ($3,311) |
| 2021 | $6,342 | 187 | Genentech USA, Inc. ($2,050) |
| 2020 | $18,361 | 128 | Celgene Corporation ($16,869) |
| 2019 | $103,522 | 224 | Novartis Pharmaceuticals Corporation ($34,674) |
| 2018 | $78,869 | 163 | Genentech USA, Inc. ($20,907) |
| 2017 | $72,553 | 163 | Genentech USA, Inc. ($24,014) |
All Payment Transactions
1,643 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Immunology | ||||||
| 12/23/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $2.36 | General |
| Category: Immunology | ||||||
| 12/20/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Consulting Fee | Cash or cash equivalent | $9,000.00 | General |
| Category: Neurology | ||||||
| 12/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $28.90 | General |
| Category: Neurology | ||||||
| 12/11/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $33.62 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $5.09 | General |
| Category: Neurology | ||||||
| 12/10/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Immune | ||||||
| 12/09/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Neurology | ||||||
| 12/05/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: PAIN | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $29.09 | General |
| Category: Neurology | ||||||
| 11/26/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.85 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 11/25/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Immunology | ||||||
| 11/21/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $9.10 | General |
| 11/20/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $1.76 | General |
| 11/19/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: Neurology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $6.95 | General |
| Category: Neurology | ||||||
| 11/18/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Neurology | ||||||
| 11/16/2024 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $300.31 | General |
| 11/16/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $86.89 | General |
| 11/16/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $74.99 | General |
| 11/16/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $33.83 | General |
| 11/14/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 436 | 56,692 | $2.5M | $1.2M |
| 2022 | 5 | 362 | 428 | $107,780 | $36,707 |
| 2021 | 8 | 400 | 474 | $108,502 | $40,811 |
| 2020 | 9 | 465 | 558 | $126,086 | $40,133 |
Total Patients
1,663
Total Services
58,152
Medicare Billing
$1.3M
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2323 | Injection, natalizumab, 1 mg | Office | 2023 | 81 | 50,718 | $1.5M | $940,191 | 61.7% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 13 | 5,403 | $850,338 | $202,904 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 125 | 148 | $30,600 | $13,798 | 45.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 75 | 182 | $63,700 | $8,775 | 13.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $4,000 | $1,959 | 49.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 25 | 29 | $10,150 | $1,814 | 17.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 15 | $3,000 | $856.11 | 28.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 15 | 31 | $4,030 | $601.79 | 14.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 23 | 34 | $1,190 | $350.18 | 29.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 22 | 79 | $2,370 | $273.95 | 11.6% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 18 | 26 | $1,300 | $22.78 | 1.8% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 11 | 12 | $48.00 | $9.10 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 200 | 251 | $57,351 | $19,934 | 34.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 66 | 76 | $24,170 | $7,851 | 32.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $9,383 | $3,353 | 35.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $8,862 | $3,110 | 35.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 49 | 54 | $8,014 | $2,459 | 30.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 179 | 231 | $50,009 | $19,546 | 39.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 49 | 52 | $15,652 | $6,345 | 40.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 86 | 95 | $13,481 | $5,155 | 38.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 26 | 26 | $8,554 | $3,089 | 36.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 19 | 20 | $6,620 | $2,157 | 32.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $5,208 | $1,840 | 35.3% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 13 | 22 | $5,346 | $1,696 | 31.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 16 | 16 | $3,632 | $982.56 | 27.1% |
About Dr. April Erwin, MD
Dr. April Erwin, MD is a Internal Medicine healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1194976670.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. April Erwin, MD has received a total of $381,757 in payments from pharmaceutical and medical device companies, with $41,748 received in 2024. These payments were reported across 1,643 transactions from 66 companies. The most common payment nature is "Consulting Fee" ($169,805).
As a Medicare-enrolled provider, Erwin has provided services to 1,663 Medicare beneficiaries, totaling 58,152 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Neurology
- Location Salt Lake City, UT
- Active Since 10/02/2008
- Last Updated 08/26/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1194976670
Products in Payments
- OCREVUS (Biological) $34,074
- Ozanimod (Drug) $30,265
- TYSABRI (Biological) $26,831
- TECFIDERA (Drug) $25,428
- Non-Covered Product (Drug) $24,014
- GILENYA (Drug) $23,790
- LEMTRADA (Drug) $20,050
- Mavenclad (Drug) $19,338
- BRIUMVI (Drug) $18,368
- ZEPOSIA (Drug) $17,662
- MAYZENT (Drug) $14,647
- AUBAGIO (Drug) $8,709
- KESIMPTA (Drug) $7,997
- Mavenclad (Biological) $7,384
- Evobrutinib $7,200
- Ocrevus (Biological) $7,180
- ARZERRA (Drug) $6,042
- UBRELVY (Drug) $1,053
- BOTOX (Biological) $522.04
- AJOVY (Biological) $468.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Salt Lake City
Dr. Willard Dere, M.d, M.D
Internal Medicine — Payments: $5.4M
Internal Medicine $5.4M
Dr. Catherine Bakewell, M.d, M.D
Internal Medicine — Payments: $1.0M
Internal Medicine $1.0M
Dr. Neeraj Agarwal, Md, MD
Internal Medicine — Payments: $344,790
Internal Medicine $344,790
George Rodgers, M.d, M.D
Internal Medicine — Payments: $229,629
Internal Medicine $229,629
James Chamberlain, Md, MD
Internal Medicine — Payments: $200,257
Internal Medicine $200,257
Schickwann Tsai, M.d, M.D
Internal Medicine — Payments: $122,681
Internal Medicine $122,681